The advent of BCR-ABL tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the
treatment of chronic myeloid leukemia (CML) patients. Mitochondria are the key organelles …

Tyrosine kinase inhibitors (TKIs) have been recognized as crucial agents for treating various
tumors, and one of their key targets is the intracellular site of the vascular endothelial growth …

Imatinib is a classical targeted drug to treat chronic myeloid leukemia (CML). However, it
shows cardiotoxicity, which limits its clinical application. Long noncoding RNA (lncRNA) …

Following an acute myocardial infarction, reperfusion of an occluded coronary artery is often
accompanied by microvascular injury, leading to worse long-term prognosis. Experimental …

Hepatocellular carcinoma (HCC) is a fatal tumor which is usually diagnosed at advanced
stage. Molecular targeted drugs were used recently to treat HCC, however, due to serious …

A growing concern of cardiotoxicity induced by PI3K inhibitors has raised the requirements
to evaluate the structure-cardiotoxicity relationship (SCR) in the development process of …

Human iPSC-derived cardiac organoids (hiPSC-COs) for cardiotoxicity drug testing via the
variety of cell lines and unestablished protocols may lead to differences in response results …

Aim With the advancement of anti-cancer medicine, cardiovascular toxicities due to cancer
therapies are common in oncology patients, resulting in increased mortality and economic …

Sorafenib, an important cancer drug in clinical practice, has caused heart problems such as
hypertension, myocardial infarction, and thrombosis. Although some mechanisms of …

Osimertinib, an irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) used for cancer treatment, can cause significant cardiac toxicity. However, the specific …